XNASTSBX
Market cap11mUSD
Dec 27, Last price
0.51USD
1D
5.35%
1Q
-8.55%
IPO
-95.30%
Name
Turnstone Biologics Corp
Chart & Performance
P/E
—
P/S
0.61
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
19m
-73.66%
Net income
-55m
L+79.02%
CFO
-66m
L-6.91%
Profile
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | |||
Revenues | 19,306 -73.66% | 73,300 -27.64% | 101,293 |
Cost of revenue | 81,138 | 107,126 | 70,312 |
Unusual Expense (Income) | |||
NOPBT | (61,832) | (33,826) | 30,981 |
NOPBT Margin | 30.59% | ||
Operating Taxes | (286) | 141 | 432 |
Tax Rate | 1.39% | ||
NOPAT | (61,546) | (33,967) | 30,549 |
Net income | (55,200) 79.02% | (30,834) -192.68% | 33,269 |
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | 77,839 | 157 | 79,954 |
BB yield | -264.51% | ||
| Debt | |||
Debt current | 4,050 | 1,961 | 659 |
Long-term debt | 4,403 | 8,371 | 4,707 |
Deferred revenue | 4,162 | 39,374 | |
Other long-term liabilities | 989 | 2,267 | 967 |
Net debt | (86,324) | (71,729) | (155,653) |
| Cash flow | |||
Cash from operating activities | (66,152) | (71,062) | (45,629) |
CAPEX | (1,249) | (5,170) | (3,406) |
Cash from investing activities | (28,093) | (14,932) | (3,348) |
Cash from financing activities | 77,046 | (2,656) | 79,954 |
FCF | (56,309) | (38,957) | |
| Balance | |||
Cash | 94,777 | 82,061 | 161,019 |
Long term investments | |||
Excess cash | 93,812 | 78,396 | 155,954 |
Stockholders' equity | (176,854) | 49,996 | 80,803 |
Invested Capital | 281,749 | (140,120) | (119,882) |
ROIC | 26.13% | ||
ROCE | 23.35% | ||
| EV | |||
Common stock shares outstanding | 11,563 | 22,189 | 22,189 |
Price | 2.55 | ||
Market cap | 29,428 | ||
EV | (56,896) | ||
EBITDA | (59,034) | (29,925) | 32,371 |
EV/EBITDA | 0.96 | ||
Interest | |||
Interest/NOPBT | |||